IK-175, an oral AHR inhibitor, as monotherapy and in combination with nivolumab in patients with urothelial carcinoma resistant/refractory to PD-1/L1 inhibitors

被引：0
作者：
Aggen, David H.
McKean, Meredith
Hoffman-Censits, Jean H.
Lakhani, Nehal J.
Alhalabi, Omar
Guancial, Elizabeth A.
Bashir, Babar
Bowman, I. Alex
Tan, Alan
Lingaraj, Trupti
Kim, Katherine
Timothy, Marissa
Ortiz-Otero, Nerymar
Bartolini, Wilmin
Kacena, Katherine
Santillana, Sergio
Luke, Jason J.
机构：
[1] Mem Sloan Kettering Canc Ctr, Genitourinary Oncol, 1275 York Ave, New York, NY 10021 USA
[2] Weill Cornell Med Coll, New York, NY USA
[3] Sarah Cannon Res Inst, Nashville, TN USA
[4] Johns Hopkins, Johns Hopkins Greenberg Bladder Canc Inst, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[5] Johns Hopkins, Johns Hopkins Greenberg Bladder Canc Inst, Sidney Kimmel Comprehens Canc Ctr, Dept Urol, Baltimore, MD USA
[6] START Midwest, Grand Rapids, MI USA
[7] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA
[8] Florida Canc Specialists & Res Inst, Sarasota, FL USA
[9] Thomas Jefferson Univ, Sarah Cannon Res Inst, Philadelphia, PA 19107 USA
[10] Thomas Jefferson Univ, Sidney Kimmel Canc Ctr, Philadelphia, PA 19107 USA
[11] Banner MD Anderson Canc Ctr, Gilbert, AZ USA
[12] Rush Univ, Med Ctr, Chicago, IL USA
[13] Ikena Oncol, Boston, MA USA
[14] UPMC Hillman Canc Ctr, Pittsburgh, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2599
引用
收藏
页数：1
相关论文
共 50 条
[31]   Impact of Timing the Combination of Radiotherapy and PD-1 Inhibitors on Outcomes in Patients with Hepatocellular Carcinoma [J].
Zhong, Liting ;
Peng, Weiwei ;
Sun, Jingyuan ;
Luo, Yongyi ;
Sheng, Hailong ;
Wu, Yi ;
Zhou, Tonggang ;
Zhou, Chaoming ;
Cao, Chuanhui .
JOURNAL OF HEPATOCELLULAR CARCINOMA, 2025, 12 :123-134
[32]   Study of PD-1 Inhibitors in Combination with Chemoradiotherapy/Chemotherapy in Patients with Esophageal Squamous Carcinoma [J].
Wei, Tianhui ;
Ti, Wenqi ;
Song, Qingxu ;
Cheng, Yufeng .
CURRENT ONCOLOGY, 2022, 29 (05) :2920-2927
[33]   PD-1/PD-L1 inhibitor monotherapy or in combination with chemotherapy as upfront treatment for advanced NSCLC with PD-L1 expression ≥ 50%: Selecting the best strategy [J].
Di Federico, Alessandro ;
De Giglio, Andrea ;
Parisi, Claudia ;
Gelsomino, Francesco ;
Ardizzoni, Andrea .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2021, 160
[34]   Outcome differences between PD-1/PD-L1 inhibitors-based monotherapy and combination treatments in NSCLC with brain metastases [J].
Haowei Wang ;
Fangfang Liu ;
Xiaoxia Chen ;
Chao Zhao ;
Xuefei Li ;
Caicun Zhou ;
Jie Hu ;
Qian Chu ;
Tao Jiang .
Experimental Hematology & Oncology, 12
[35]   Outcome differences between PD-1/PD-L1 inhibitors-based monotherapy and combination treatments in NSCLC with brain metastases [J].
Wang, Haowei ;
Liu, Fangfang ;
Chen, Xiaoxia ;
Zhao, Chao ;
Li, Xuefei ;
Zhou, Caicun ;
Hu, Jie ;
Chu, Qian ;
Jiang, Tao .
EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2023, 12 (01)
[36]   Prognostic Value of PD-1 and PD-L1 Expression in Patients with High Grade Upper Tract Urothelial Carcinoma [J].
Krabbe, Laura-Maria ;
Heitplatz, Barbara ;
Preuss, Sina ;
Hutchinson, Ryan C. ;
Woldu, Solomon L. ;
Singla, Nirmish ;
Boegemann, Martin ;
Wood, Christopher G. ;
Karam, Jose A. ;
Weizer, Alon Z. ;
Raman, Jay D. ;
Remzi, Mesut ;
Rioux-Leclercq, Nathalie ;
Haitel, Andrea ;
Rapoport, Leonid M. ;
Glybochko, Peter V. ;
Roscigno, Marco ;
Bolenz, Christian ;
Bensalah, Karim ;
Sagalowsky, Arthur I. ;
Shariat, Shahrokh F. ;
Lotan, Yair ;
Xylinas, Evanguelos ;
Margulis, Vitaly .
JOURNAL OF UROLOGY, 2017, 198 (06) :1254-1263
[37]   PHASE 1 STUDY OF THE PORCUPINE (PORCN) INHIBITOR RXC004 IN COMBINATION WITH THE PD-1 INHIBITOR NIVOLUMAB IN PATIENTS WITH ADVANCED SOLID TUMORS [J].
Cook, Natalie ;
Blagden, Sarah ;
Lopez, Juanita ;
Sarker, Debashis ;
Greystoke, Alastair ;
Bashir, Saira ;
Skolariki, Aglaia ;
ElBadri, Salma ;
Morton, Cienne ;
OrtegoFranco, Ana ;
MohamedKhan, Shybi ;
Eagle, Catherine ;
Flanagan, Eimear ;
Goodwin, Louise ;
Phillips, Caroline ;
Robertson, Jane ;
Tilston, Craig ;
Timmis, Helen ;
Woodcock, Simon ;
Plummer, Ruth .
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 :A752-A752
[38]   PD-1/PD-L1 inhibitor monotherapy in recurrent or metastatic squamous cell carcinoma of the head and neck: a meta-analysis [J].
Chen, Long ;
Mo, Dun-Chang ;
Hu, Min ;
Zhao, Shi-Jie ;
Yang, Qiang-Wei ;
Huang, Zhi-Ling .
AMERICAN JOURNAL OF OTOLARYNGOLOGY, 2022, 43 (02)
[39]   Combined immunotherapy with ipilimumab plus nivolumab in metastatic PD-1/PD-L1-refractory Merkel cell carcinoma-a case report [J].
Leven, Anna-Sophia ;
Becker, Juergen C. ;
Poettgen, Christoph ;
Schadendorf, Dirk ;
Ugurel, Selma ;
Tasdogan, Alpaslan .
INTERNATIONAL JOURNAL OF DERMATOLOGY, 2024, 63 (02) :e69-e71
[40]   Enhanced programmed death 1 (PD-1) and PD-1 ligand (PD-L1) expression in patients with actinic cheilitis and oral squamous cell carcinoma [J].
Tatiana Salles de Souza Malaspina ;
Thaís Helena Gasparoto ;
Maria Renata Sales Nogueira Costa ;
Edgard Franco de Melo ;
Maura Rosane Valério Ikoma ;
José Humberto Damante ;
Karen Angélica Cavassani ;
Gustavo Pompermaier Garlet ;
João Santana da Silva ;
Ana Paula Campanelli .
Cancer Immunology, Immunotherapy, 2011, 60 :965-974
12345